Coloplast Archives - Medical Design Sourcing

These devices are the top targets of lawsuit-related advertisements

Surgical mesh products continue to drive medical device lawsuit spending. [Photo via Adobe Stock]

Spending on advertisements related to medical device lawsuits this year is on track to exceed last year’s tally.

That’s according to figures provided by Washington, D.C.-based X Ante, which uses data from ad intelligence firm Vivvix. X Ante supplies reports on medical device lawsuit ad spending to the Advanced Medical Technology Association (AdvaMed), which is calling for new federal regulations of mass tort advertising to protect device manufacturers from lawsuits bankrolled by third-party funders.

For the first half of 2023, $6.2 million worth of legal ads targeted five kinds of medical devices:

Pelvic mesh: $3.5 million Hernia mesh: $1.9 million CPAP machines: $532,000 Physiomesh: $262,000 Military earplugs: $54,000

Spending on the top five device categories totaled just under $11 mil…

Coloplast to acquire wound care company Kerecis for $1.3B

Coloplast plans to acquire Kerecis and its SurgiBind fish skin wound care biologic. [Image from Kerecis]Coloplast announced today that it entered into an agreement to sign Kerecis, a developer of biologics for the wound care market.

The agreement has a total value reaching up to $1.3 billion. Of that, Coloplast intends to pay $1.2 billion in an upfront cash payment.

Denmark-based Coloplast sees Kerecis as an “attractive opportunity” to strengthen its presence in the advanced wound care market, according to a news release. The purchase would allow the company to enter the high-growth, U.S.-centric biologics segment.

Kerecis developed and patented a clinically differentiated, sustainable and scalable technology platform based on intact fish skin. It retains its similarity to human skin while production requires minimal processing. Coloplast said this results in improved wound healing. Since launching its product in 2016, Kerecis has grown quickly …

Coloplast wins summary judgement in transvaginal mesh suit in Minnesota

A federal judge in Minnesota granted summary judgment to Coloplast in a lawsuit over the company’s transvaginal mesh.

Angela Dawn Cantrell received the Restorelle L mesh implant as part of a surgery to correct vaginal prolapse in January 2018. Cantrell continued to experience pain and pelvic floor dysfunction after the surgery and underwent additional surgeries.

In 2020, Cantrell commenced action, advancing 11 claims against Coloplast, which now moves for summary judgment and to exclude the opinions and testimony of Cantrell’s six expert witnesses. Cantrell opposed the motions but only contests the motion for summary judgment as to three of the 11 claims: negligent design, design defect and failure to warn.

Coloplast argued that the negligent design claim fails because of a lack of admissible specific causation evidence. The court excluded testimony of Cantrell’s two specific causation experts, meaning she can’t succeed on the cla…

Ambu replaces CEO with new leadership

Britt Meelby Jensen is the new CEO of Ambu (Photo via Atos Medical)

Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow.

“Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a news release. “However, the COVID-19 pandemic, the recent macroeconomic headwind and a weaker than originally expected financial performance require that we execute differently on our strategy.”

Jørgen Jensen said Ambu’s overall strategic direction has not changed but that the board, Britt Meelby Jensen and her leadership team will “evaluate the need for tactical and operational adjustments to the strategy.”

Get the full story at our sister site, MassDevice.

Ambu replaces CEO with new leadership

Britt Meelby Jensen is the new CEO of Ambu (Photo via Atos Medical)

Ambu today said it has hired Board Member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez effective tomorrow.

“Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a news release. “However, the COVID-19 pandemic, the recent macroeconomic headwind and a weaker than originally expected financial performance require that we execute differently on our strategy.”

Jørgen Jensen said Ambu’s overall strategic direction has not changed, but that the board, Britt Meelby Jensen and her leadership team will “evaluate the need for tactical and operational adjustments to the strategy.”

“With more than 20 years of experience within healthcare and general management, and her work o…

Coloplast to buy Atos Medical for more than $2B

Coloplast will spend 16 billion DKK kr. (roughly $2.4 billion) to acquire laryngectomy care device company Atos Medical.

The Danish medtech giant in a Monday news release said Atos Medical’s goal of making life easier for people living with a neck stoma closely aligns with Coloplast’s purpose to serve people with intimate healthcare needs.

Paris-based private equity outfit PAI Partners is Malmö, Sweden–based Atos Medical’s present owner. Officials at the companies expect the deal to close early next year during the second quarter of Coloplast’s 2021-22 fiscal year, pending customary regulatory approvals.

Atos Medical will operate as a separate strategic business unit inside Coloplast once the deal is complete. It presently has a presence in 22 countries, including a U.S. location in New Berlin, Wisconsin.